Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer.
JAMA Oncol
; 8(11): 1694-1696, 2022 11 01.
Article
em En
| MEDLINE
| ID: mdl-36136305
This cohort study assesses the capacity of passive immunization and tixagevimab and cilgavimab to inhibit interaction between receptor-binding domains and angiotensin-converting enzyme 2 in patients with hemato-oncologic diseases.
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
COVID-19
/
Neoplasias
Tipo de estudo:
Observational_studies
Limite:
Humans
Idioma:
En
Revista:
JAMA Oncol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Áustria